Just published! The first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. Researchers at Washington University School of Medicine in St. Louis used Alamar's NULISAseq™ CNS 120 Panel to analyze more than 2,300 plasma samples, finding that biomarkers associated with amyloid clearance differed from those associated with cognitive decline in patients receiving lecanemab. By measuring brain-derived tau alongside more than 100 additional proteins, investigators were able to track pathology and treatment response in a single assay, uncovering biological changes that may be missed when evaluating only a small number of biomarkers. As anti-amyloid therapies become part of routine care, precision proteomics is opening a new window into researching how patients respond to treatment. Read the full press release: na2.hubs.ly/H080hnS0 #PrecisionProteomics #AlzheimersResearch #Biomarkers #Neuroscience #NULISA

⏰ Coming up tomorrow: Rethinking ALS Biomarkers   There’s still time to register for a closer look at how ultra-sensitive proteomics is advancing ALS research.   Hear from Prof. Alberto Catanese (RWTH Aachen University) and Clare Paterson, PhD (Alamar Biosciences) as they explore emerging insights into ALS biology and the potential of high-sensitivity protein detection to uncover biomarkers that have historically been difficult to measure.   Tune in tomorrow to explore the latest ALS biomarker research, followed by a live Q&A with the speakers.   👉 Register now: na2.hubs.ly/H07ZTgg0

🕛 Happening Tomorrow: IMID Webinar   Don’t miss the opportunity to hear emerging research and biomarker insights across immune-mediated inflammatory diseases (IMIDs).   Join Dr. Chris Wincup (King’s College London), Dr. Felix Wohlrab (Charité – Universitätsmedizin Berlin), and Dr. Jasmine Sim (Newcastle University) as they share new findings generated using NULISA™ technology across multiple IMID indications.   Discover what ultra-sensitive proteomics is revealing about disease biology and shared inflammatory pathways in tomorrow's webinar, then join the conversation during a live expert panel discussion.   🗓️ Thursday, September 24 ⏰ 3:00–5:30 PM BST   Register now: na2.hubs.ly/H07ZTfq0   #Immunology #AutoimmuneDisease #Inflammation #IMID #MultipleSclerosis #IBD #RheumatoidArthritis #Lupus #Asthma

Today is World Alzheimer’s Day 🧠 More than 55 million people worldwide are living with dementia, including over 7 million Americans living with Alzheimer’s disease. At Alamar Biosciences, we recognize the importance of advancing research that deepens our understanding of neurodegenerative disease and helps move the field toward earlier detection and better outcomes. This #WorldAlzheimersDay, we join the global community in raising awareness and supporting everyone impacted by Alzheimer’s and other dementias. Learn more about these tips from the @alzassociation: 10 Early Signs and Symptoms of Alzheimer’s & Dementia: bit.ly/3V54niD Ways to Support Brain Health: bit.ly/4hkuERi #WorldAlzheimersDay #AlzheimersAwareness #AlzheimersResearch #Neuroscience #Proteomics

AAIC Day 1 ✅ The highlight? The conversations. Thanks to the researchers, collaborators, and new connections who stopped by Booth 530 today. We're excited to see the momentum behind proteomics in Alzheimer's research. #AAIC26 #Alzheimers

The past week marked an important milestone for Alamar. Our focus remains the same: powering precision proteomics to enable earlier disease detection. We’re grateful to our community and energized for what’s ahead. #NasdaqListed $ALMR

We’re proud to share new clinical findings on brain-derived pTau unveiled at #AAIC25! Over 30+ presentations and posters feature groundbreaking NULISA™ data advancing early, blood-based detection of neurodegenerative disease. 👉 Read the press release: bit.ly/4566rIh

🧠 NULISA™ is making waves. Thought leaders say it’s closing key gaps in CNS biomarker discovery and enabling blood-based diagnostics. AlzForum highlights 7 Alzheimer’s & Dementia studies showing how our platform is transforming neuro research. Dive in: bit.ly/46lj84g

We are proud to be a Gold Sponsor of this year’s CIBERNED International Conference on Neuroinflammation, Aging and Neurodegeneration. Don’t miss our featured talk showcasing #NULISA. Learn more: ow.ly/kRry50VZKlw #Neurodegeneration #Biomarkers #Proteomics #CIBERNED2025

🧠 Advancing Biomarker Discovery in #Neurodegeneration with MULTIPLEX analysis using Dried Blood & Plasma Spots 🔍 See poster No. 607 at #ADPD2025, April 4-5, where we evaluated 120 neurodegenerative and inflammatory proteins across multiple microsampling formats with #NULISA.

🧠 Experience pTau and Beyond at #ADPD2025! 📅 Product Theater: Thursday, April 3 | 10:40–11:10 AM 🧾12 posters with NULISA data 👋 Booth #22C: Demo the ARGO HT System ow.ly/ktvs50VoYQM #Neurodegeneration #Biomarkers #Alzheimers #Parkinsons #Proteomics #NULISA #ARGOHT

2024 has been a remarkable year of breakthroughs and milestones for Alamar Biosciences, and we owe it all to our incredible team, customers and supporters. Thank you for being part of our journey! Here’s to continued success and innovation in 2025—Happy New Year! 🌟

✈️ Kicking off September in Cambridge, UK! Join us next week at the 2024 Meeting of the International Neurotrauma Society (INTS), to learn about the groundbreaking research powered by the #NULISA Platform. See you there! 👋 ow.ly/oABv50TaoBa #INTS2024

🎙️Join us for the latest episode of Mendelspod as we deep dive into the groundbreaking advancements in #Alzheimer's research with Dr. Henrik Zetterberg, one of the world's leading experts from the University of Gothenburg. New episode out now 👉 ow.ly/FJ6150Sxr08

We are here live at the 2nd Annual Symposium for Human Proteome and Health! Join us at 09:45 for an exclusive look at the next generation of #proteomics technology and learn about the cutting-edge capabilities of #NULISA. Learn more 👉 ow.ly/Wr6t50SqxbW

Exciting news! We are joining forces with the Biomarkers of Aging Consortium to revolutionize longevity research! Read the release! ow.ly/vrmF50SqTcw

#FOCIS2024 day 1 is underway! Meet us during the poster session to hear Alamar's Xiao-Jun Ma and Stanford University's Dr. Holden Maecker share data about the cutting-edge capabilities of #NULISA and the #ARGO HT System. Swing by booth 112 to learn more 👉ow.ly/TBYm50SjiYV

Happening today! Join us at #FOGBoston to learn about #NULISA, using precision proteomics for early disease detection. Meet us on the Omics Stage at 4:50pm to hear how this technology is changing the field of #Alzheimer’s Disease research. Learn more 👉 ow.ly/y8x350SfrvO

See you at #FOGBoston this week! Don't miss our presentation Wed, June 12 at 4:50pm on the Omics Stage to hear Alex Forrest-Hay, introduce #NULISA, a groundbreaking protein #biomarker detection platform applying precision #proteomics for early disease detection. See you there!

Progress in translational research has been impeded by a lack of highly multiplexed and ultrasensitive proteomic technologies. #NULISA is changing the way we profile proteins from biofluids. Stop by our poster to learn more! ow.ly/bW5O50S6rgx #KSNeurodegen24